



## Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

### Health Advance Inc.

9131 Keele Street, Suite A4  
Vaughan, Ontario, Canada L4K 0G7  
(705) 733-7098

[www.HealthAdvanceGroup.com](http://www.HealthAdvanceGroup.com)

[President@HealthAdvanceGroup.com](mailto:President@HealthAdvanceGroup.com)

SIC Code 5990 - Retail-Retail Stores – Other Specialty Retail

## Annual Report

For the Twelve Months Ending March 31, 2025  
(the "Reporting Period")

### Outstanding Shares

The number of shares outstanding of our Common Stock was:

553,999,524 as of the end of this reporting period, March 31, 2025  
185,947,500 as of the end of the most recent fiscal year, March 31, 2024

### Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes:  No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes:  No:

### Change in Control

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

Yes:  No:

<sup>1</sup> "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any).** In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

HEALTH ADVANCE INC.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

WYOMING, APRIL 14, 2010, ACTIVE

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

NONE

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

NONE

The address(es) of the issuer's principal executive office:

9131 KEELE STREET, SUITE A4  
VAUGHAN, ONTARIO L4K 0G7  
CANADA

The address(es) of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No:

## **2) Security Information**

### Transfer Agent

Equity Trust Company, LLC  
48 Wall Street, Floor 23  
New York, New York  
10005

### Publicly Quoted or Traded Securities:

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol:	HADV		
Exact title and class of securities outstanding:	COMMON SHARES		
CUSIP:	42225L203		
Par or stated value:	.001		
Total shares authorized:	990,000,000	as of date:	Mar 31, 2025
Total shares outstanding:	553,999,524	as of date:	Mar 31, 2025
Total number of shareholders of record:	72	as of date:	Mar 31, 2025

*All additional class(es) of publicly quoted or traded securities (if any):* Not Applicable

### Security Description:

*The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:*

**1. For common equity, describe any dividend, voting and preemption rights.**

One vote per share. No special dividend, voting and preemption rights.

**2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

None issued during the reporting period. A correction to be made to a 2017 Board of Directors resolution that should have been filed with Wyoming in 2017, in which a Series A Preferred Share Class was authorized to be created at the time, and was to be filed as a Certificate of Designation outlining the characteristics and quantity of the Preferred Shares at the time, has been addressed and corrected in January 2025. The effect of this correction, when the preferred shares are issued, will be to make the president who is serving at the time of the correction, Larry McLachlin, the holder of effective voting control. These shares have not yet been issued, and no change of control has yet occurred, but will in the future with this issuance.

**3. Describe any other material rights of common or preferred stockholders.**

There are no undisclosed material enforceable rights, beyond the circumstances of the issuer as described in the issuer's filings. The reader is encouraged to read all notes to all tables in this report and notes to the financial statements in this report, and to read and understand the disclosure of the Annual Reports for the years ending March 31, 2020 - 2025 in order to understand the issuer's history, and the evolution of its management (and policies).

**4. Describe any material modifications to the rights of holders of the company's securities that have occurred over the reporting period covered by this report.**

Not applicable.

### 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### A. Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No:  Yes:  (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: March 31, 2022									
<u>Opening Balance</u>									
Date April 1/2022									
Common: 160,947,500									
Preferred: N/A									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
Apr 25/22	New	12,500,000	Common	0.01	No	JP Carey Enterprises, LP/ Joe Canouse	Working Capital	Unrestricted	Approved Regulation A+
May 02/22	New	12,500,000	Common	0.01	No	World Market Ventures/ Chad Curtis	Working Capital	Unrestricted	Approved Regulation A+
Jun 27/24	New	18,421,052	Common	.0011	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Jul 17/24	New	22,174,535	Common	.0007	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Aug 09/24	New	24,393,939	Common	.00066	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144

Aug 20/24	New	26,833,333	Common	.0006	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Sep 04/24	New	29,479,166	Common	.00048	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Sep 23/24	New	32,291,666	Common	.00048	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Oct 14/24	New	34,000,000	Common	.0003	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Nov 11/24	New	39,000,000	Common	.0005	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Nov 29/24	New	42,500,000	Common	.0003	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Feb 07, 2025	New	47,083,333	Common	.00024	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Feb 28, 2025	New	51,875,000	Common	.00024	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144

Shares Outstanding on Date of This Report:

Ending Balance:

Date March 31, 2025

Common: 553,999,524

Preferred: N/A

**GENERAL ADVISORY COMMENT**

The shares issued in 2022 were pursuant to an approved Tier 1, Regulation A+ offering.

**B. Promissory and Convertible Notes**

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities :

No:  Yes: X (If yes, you must complete the table below)

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion <sup>6</sup>	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
Mar 10/17	10,000	15,337	Mar 03/18	40% Disc	0	64,000,000	GHS Investments Mark Grober	Note 1
Mar 20/19	2,500	62,000	Mar 20/20	TBD	0	0	Fit For A King Gerry Pettie	Note 2
May 25/21	20,697	20,697	May 25/22	\$0.025	0	828,000	Sydney Bernstein	Note 3
May 27/21	20,697	20,697	May 27/22	\$0.025	0	828,000	Arthur Stemmerman	Note 4

<sup>6</sup> The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

Jun 02/21	20,697	20,697	Jun 02/22	\$0.025	0	828,000	Originally Luigi Buttino; Purchased by Gerald Pettle	Note 5
Jul 07/21	20,697	20,697	Jul 07/22	\$0.025	0	828,000	Ne'eman Foundation Charm Katz	Note 6
Oct 27/21	72,000	72,000	Oct 27/22	40% Disc	0	300,000,000	JP Carey Limited Partnership Joe Canouse	Note 7
Jan 27/22	57,000	57,000	Jan 27/23	40% Disc	368,052,027	160,988,520	JP Carey Limited Partnership Joe Canouse	Note 8
<b>Total Outstanding Balance:</b>		\$289,125	<b>Total Shares:</b>		368,052,027	528,300,520		

#### Note 1

The holder has agreed to convert for equity when suitable and possible.

#### Note 2

Fit For A King, Inc, the owner of record of approximately 30 million common shares, and Fit For A King's beneficial owner, Gerald Pettle, undertook to provide the issuer with working capital in 2019, and thereafter. This was to be for the purpose of attaining OTC Markets current information designation, as well as for the issuer to attain good standing with any other applicable regulatory bodies and suppliers. Compensation to Mr. Pettle is to be eventual repayment in cash with bonus and/or shares, to be determined. Additional possible financial compensation to Mr. Pettle was to be linked to, and/or governed by, the success of business ventures that Mr. Pettle would bring to the issuer in the past, present or future. Such compensation can also either take the form of cash and/or shares. Compensation to Mr. Pettle for earlier assistance will be determined by the issuer's circumstances at the time(s) that compensation to Mr. Pettle is made. Determinations at such time(s) will also take into account compensation required for 3<sup>rd</sup> parties who are performing supportive roles in retaining OTC Markets good standing, paying other regulatory compliance costs, retiring creditor obligations, and funding or operating business projects. This accommodation of 3<sup>rd</sup> parties will include compensation to issuer management to market norm standards currently and retroactively, third-party consultants, and any other compensatory arrangements with parties, including staff, who contribute to attainment of the issuer's goals, or payment by them on behalf of the issuer for costs or processes needed to operate the issuer's business. This debt is included in the "convertible debt" table not because the debt is immediately convertible but rather that it may become convertible in the future under terms that are not yet known, and are not presently enforceable.

#### Note 3

At the time of the filing of this report, management believes that the creditor prefers to receive repayment in cash, rather than conversion.

#### Note 4

At the time of the filing of this report, management believes that the creditor prefers to receive repayment in cash, rather than conversion.

#### Note 5

At the time of the filing of this report, management believes that the creditor prefers to receive repayment in cash, rather than conversion and that the note has been purchased by Gerald Pettle.

#### Note 6

At the time of the filing of this report, management believes that the creditor prefers to receive repayment in cash, rather than conversion.

#### Note 7

At the time of the filing of this report, this note is in default. Remedying the default is being discussed with the creditor and involves special interest and/or penalties to be determined as conversions are effected. A restatement of the principal amount due may be required to reflect the specifics of such forbearance.

## Note 8

As subsequent event to the Annual Report reporting period, a final settlement and payment of this note in full has been completed. The treatment of this settlement in the capital structure will be reflected in the Q1 2025 report for the period ending June 30, 2025.

### 4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

#### **CBD BEVERAGES LEADING TO THE CANNABIS SECTOR MORE BROADLY and ADDITIONAL OPPORTUNITIES**

In earlier reporting periods, Health Advance Inc had taken steps to launch proprietary CBD infused dealcoholized wine beverage products and to investigate the viability of launching proprietary nutraceutical products.

Health Advance's test CBD beverage production took place via the operating entity Courtship Wines, a New York private company, of which Health Advance was 50% owner. Negotiations for the sale of this test production had been underway with a U.S. regional grocery chain operating approximately 400 stores. The prospective customer stipulated conditions which the issuer had been evaluating.

These conditions included repackaging the goods, guaranteed sale, etc. It was determined by the project management team that test marketing through a brand-owned website would be more fruitful because it could be carried out sooner, without changes to the product. Test sales to consumers were carried out.

By March 31, 2024, the date of the issuer's last annual report, management of the issuer derived the following conclusion from the aforementioned test marketing - Health Advance should seek a broader approach to cannabis related business opportunities, rather than exclusively through CBD infusion of wine, such as other substances, other beverages, new partnerships and alliances.

Accordingly, in 2024 Health Advance entered into joint venture negotiations with emergent cannabis processing operations, such as Coulson Cannabis, and the SoEquity Project.

Of the two, negotiations with the SoEquity Project are most advanced. This can be seen on the websites [www.CourtshipWines.com](http://www.CourtshipWines.com) and [www.SoEquityCorporation.com](http://www.SoEquityCorporation.com).

Interest by Health Advance in this field continues to be justified by industry watchers, and in the popular press, such as this article by Newsweek, which is representative of the genre, LINK: <https://www.newsweek.com/what-are-cannabis-cocktails-will-they-replace-alcohol-2030717>

Health Advance may benefit from the SoEquity Project through the provision of non-dilutional working capital and project resources from SoEquity's intended Regulation A+ Tier 2 public offering, if such occurs.

B. List any subsidiaries, parent company, or affiliated companies.

Affiliated: Courtship Wines, Inc. New York State. Would 49% in the latest state of negotiation with the SoEquity Project. The entity is treated as separate for accounting purposes, as a JV, rather than being combined and consolidated for reporting purposes.

C. Describe the issuers' principal products or services.

- CBD or other cannabis derivatives infused into beverages where legal, subject to commercial customer vetting. Testing, likely new variants required.
- Immune boosting nutraceutical, and/or female health product(s) and/or medical equipment, in viability analysis. Market research stage.
- Consulting in the realm of marketing and distribution in fields that are adjacent to human wellness.

## 5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used, or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties, or facilities of the issuer, give the location of the principal plants and other property of the issuer, and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties, or facilities, clearly describe them as above and the terms of their leases.

Health Advance former management was in the past not local to the Company's official business address. Current management has rectified this situation, as shown below in the photograph of Health Advance Inc physical business address.



*Health Advance occupies a modern shared-use office premises within reasonable proximity of management, consultants, and service providers.*



*The facility accommodates all foreseeable meeting and collaboration requirements at modest rent within industry norms.*

## 6) All Officers, Directors, and 5% Beneficial Owners of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

*The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.*

<b>Individual Name</b> (First, Last) or <b>Entity Name</b> (Include names of control person(s) if a corporate entity)	<b>Position/Company</b> <b>Affiliation</b> (ex: CEO, ≥ 5% beneficial owner)	<b>City and State</b> (Include Country if outside U.S.)	<b>Number of</b> <b>Shares</b> <b>Owned</b> (List common, preferred, warrants and options separately)	<b>Class of</b> <b>Shares</b> <b>Owned</b>	<b>Percentage of</b> <b>Class of</b> <b>Shares</b> <b>Owned</b> (undiluted)
Larry McLachlin	Chair, President	Blue Mountains, Ontario, Canada	80,000	Common	.0001%
Micro MedTech Windell Abraham See Note A	> 5%	Pohnpei, Micronesia	40,000,000	Common	6%
Fit For A King	Consulting Shareholder	Stouffville, Ontario, Canada	30,005,500	Common	4%

**Note A:** These shares, which had formed part of a voting arrangement that conveys continuing proxy to operating management, were subject to certain performance expectations during a vesting period at the time of issuance. These shares have been, and are still, subject to review and cancellation by the issuer at any time for contract reasons without further notice, as attested to by the publication of this advisory, which is made as a courtesy to any affected parties continuously. This advisory is made without waiving the cancellation rights of the issuer.

## 7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

**No**

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

**No**

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

**No**

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

**No**

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

**No**

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

**No**

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

NOT APPLICABLE

## 8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

### Securities Counsel

Name: VIC DEVLAEINCK  
Firm: ATTORNEY - CPA  
Address 1: 100013 N.E.HAZEL DELL AVENUE, SUITE 317  
Address 2: VANCOUVER, WASHINGTON, 98685  
Phone: (503) 806-3533  
Email: VIC@VICDEVLAEINCK.COM

### Accountant

Name: INTERNAL

### Investor Relations

Name: INTERNAL

### *All other means of Investor Communication:*

Twitter: [www.Twitter.com/HADVPresident](http://www.Twitter.com/HADVPresident)

### Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Firm: Winning Brands Corporation (Delaware)  
Nature of Services: Consulting  
Address 1: C/O National Registered Agents  
Address 2: 160 Greentree Drive, Suite 101, Dover, DE 19904  
Phone: (705) 737-4062  
Email: CustomerService@WinningBrands.ca

## 9) Financial Statements

A This Disclosure Statement was prepared by

Name	Larry McLachlin
Title	President
Relationship	Officer of Health Advance

B The following financial statements were prepared in accordance with:

IFRS  
 U.S. GAAP

C The following financial statements were prepared by (name of individual)<sup>2</sup>:

Name:	Daniela Relja
Title:	ProtectCor Services
Relationship:	Bookkeeping and Administrative Service Provider

Describe the qualifications of the person or persons who prepared the financial statements:  
**5 Years Direct Experience**

Provide the following financial statements for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Important Notes:

- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- All financial statements for a fiscal period must be published together with the disclosure statement in one Annual or Quarterly Report.

---

<sup>2</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

## 10) Issuer Certification

*Principal Executive and Financial Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Larry McLachlin, certify that:

1. I have reviewed this Disclosure Statement for Health Advance Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

July 14, 2025

/s/ LARRY MCLACHLIN

CHAIRMAN & CEO

# Financial Statements of Health Advance, Inc

**For the Twelve Months Ending March 31, 2025**

(Unaudited)

*These financial statements are to be read in conjunction with the accompanying notes,  
which form an integral part of their presentation.*

# Health Advance Inc.

## Balance Sheet

As of March 31, 2025

(Unaudited)

	TOTAL	
	AS OF MAR. 31, 2025	AS OF MAR. 31, 2024 (PY)
<b>Assets</b>		
Current Assets		
Cash and Cash Equivalent	\$ -780.72	\$287.36
Accounts Receivable (A/R)		
Accounts Receivable (A/R) - CAD Accounts	6,225.99	6,225.99
Accounts Receivable (A/R) - US Accounts	30,000.00	30,000.00
<b>Total Accounts Receivable (A/R)</b>	<b>\$36,225.99</b>	<b>\$36,225.99</b>
Loan to Courtship Wines (CDN Funds)	91,417.31	91,417.31
Loan to Courtship Wines (USD Funds)	191,700.00	191,700.00
<b>Total Current Assets</b>	<b>\$318,562.58</b>	<b>\$319,630.66</b>
Non-current Assets		
Property, plant and equipment	\$1,648.62	\$1,648.62
Intellectual Property	180,000.00	180,000.00
<b>Total Non Current Assets</b>	<b>\$181,648.62</b>	<b>\$181,648.62</b>
<b>Total Assets</b>	<b>\$500,211.20</b>	<b>\$501,279.28</b>
<b>Liabilities and Equity</b>		
Liabilities		
Current Liabilities		
Accounts Payable (A/P)	\$297,018.32	\$268,803.93
Accrued Liabilities	2,500.00	2,500.00
Loan (Short Term) from FNL	3,862.93	
Loan (Short Term) from HADV President	9,429.47	8,164.81
Loan (Short Term) from Investor	21,065.00	
Loan (Short Term) from new JV Partner	8,649.99	9,792.04
<b>Total Current Liabilities</b>	<b>\$342,525.71</b>	<b>\$289,260.78</b>
Non-current Liabilities		
Loan from Fit-For-A-King Inc.	61,935.90	61,935.90
Promissory Notes CDN	82,135.43	82,135.43
Promissory Notes USD	110,000.00	110,000.00
<b>Total Non-current Liabilities</b>	<b>\$254,071.33</b>	<b>\$254,071.33</b>
<b>Total Liabilities</b>	<b>\$596,597.04</b>	<b>\$543,332.11</b>
Equity		
Accumulated Deficit	-437,495.00	-437,495.00
Additional Paid-In Capital	186,080.00	186,080.00
Common Stock	553,062.00	553,062.00
Common Stock to be Issued	67,500.00	67,500.00
Retained Earnings	-411,199.83	-362,108.47
Profit for the year	-54,333.01	-49,091.36
<b>Total Equity</b>	<b>\$ -96,385.84</b>	<b>\$ -42,052.83</b>
<b>Total Liabilities and Equity</b>	<b>\$500,211.20</b>	<b>\$501,279.28</b>

# Health Advance Inc.

## Profit and Loss

April 2024 - March 2025

(Unaudited)

	TOTAL	
	APR. 2024 - MAR. 2025	APR. 2023 - MAR. 2024 (PY)
<b>EXPENSES</b>		
Bank Charges	319.19	290.14
Business Travel Expenses	<b>417.67</b>	<b>68.91</b>
Compliance and Transfer Agent	13,248.10	9,695.85
Executive Compensation	12,943.56	13,346.46
Interest expense	1,000.00	771.91
Investor Relations	3,598.00	
IT Expenses	282.80	379.96
Occupancy	819.59	627.85
Office Administration and Bookkeeping	19,775.02	20,104.99
Professional Fees		
Legal	1,500.00	3,415.09
<b>Total Professional Fees</b>	<b>1,500.00</b>	<b>3,415.09</b>
Sales Tax Paid	173.31	187.87
<b>Total Expenses</b>	<b>\$54,077.24</b>	<b>\$48,889.03</b>
<b>OTHER EXPENSES</b>		
Exchange Gain or Loss	255.77	202.33
<b>Total Other Expenses</b>	<b>\$255.77</b>	<b>\$202.33</b>
<b>PROFIT</b>	<b>\$ -54,333.01</b>	<b>\$ -49,091.36</b>

# Health Advance Inc.

## Statement of Cash Flows

April 2024 - March 2025

(Unaudited)

	TOTAL
<b>OPERATING ACTIVITIES</b>	
Net Income	-54,333.01
Adjustments to reconcile Net Income to Net Cash provided by operations:	
Accounts Payable (A/P) - CAD Suppliers (USD)	31,031.29
Accounts Payable (A/P) - US Suppliers (USD)	-2,816.90
Loan (Short Term) from FNL	3,862.93
Loan (Short Term) from HADV President	1,264.66
Loan (Short Term) from Investor	21,065.00
Loan (Short Term) from new JV Partner	-1,142.05
<b>Total Adjustments to reconcile Net Income to Net Cash provided by operations:</b>	<b>53,264.93</b>
<b>Net cash provided by operating activities</b>	<b>\$ -1,068.08</b>
<b>NET CASH INCREASE FOR PERIOD</b>	<b>\$ -1,068.08</b>
Cash at beginning of period	287.36
<b>CASH AT END OF PERIOD</b>	<b>\$ -780.72</b>

# Health Advance Inc.

## Statement of Cash Flows

April 2023 - March 2024

(Unaudited)

	TOTAL
<b>OPERATING ACTIVITIES</b>	
Net Income	-49,091.36
Adjustments to reconcile Net Income to Net Cash provided by operations:	
Accounts Payable (A/P) - CAD Suppliers (USD)	31,212.88
Accounts Payable (A/P) - US Suppliers (USD)	6,225.93
Loan (Short Term) from HADV President	771.91
Loan (Short Term) from new JV Partner	2,782.10
<b>Total Adjustments to reconcile Net Income to Net Cash provided by operations:</b>	<b>40,992.82</b>
<b>Net cash provided by operating activities</b>	<b>\$ -8,098.54</b>
<b>NET CASH INCREASE FOR PERIOD</b>	<b>\$ -8,098.54</b>
Cash at beginning of period	8,385.90
<b>CASH AT END OF PERIOD</b>	<b>\$287.36</b>

# Health Advance Inc.

## Statement of changes in equity

As of March 31, 2025

(Unaudited)

	TOTAL	
	AS OF MAR. 31, 2025	AS OF MAR. 31, 2024 (PY)
Accumulated Deficit	-437,495.00	-437,495.00
Additional Paid-In Capital	186,080.00	186,080.00
Common Stock	553,062.00	553,062.00
Common Stock to be Issued	67,500.00	67,500.00
Retained Earnings	-411,199.83	-362,108.47
<b>Total Equity</b>	<b>\$ -42,052.83</b>	<b>\$7,038.53</b>

## **NOTES TO THE FINANCIAL STATEMENTS OF HEALTH ADVANCE INC**

### **For the Twelve Months Ending March 31, 2025**

#### **1. NATURE OF OPERATIONS AND ORGANIZATION**

Health Advance Inc. (the “Company” or “Health Advance”) was incorporated on April 14, 2010 in the State of Wyoming. The Company was originally a development stage online retailer of home medical products. Since that time, the Company has pursued broader business opportunities in the field of human wellness. The Company is in good standing with the State of Wyoming.

#### **2. BASIS OF PRESENTATION**

The condensed financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the USA for the Alternative Reporting Guidelines of OTC Markets. All adjustments, consisting of normal recurring accruals, considered necessary for a fair presentation have been included. Restatement of capital stock attributed value, and additional paid in contributions, will be made when required in future financial statements, without amendment of prior reporting, in order to reflect the interest impact of negotiated settlement of loans in forbearance, or changes to the convertibility of promissory notes and other obligations, when applicable negotiations are completed.

#### **3. GOING CONCERN**

These financial statements have been prepared assuming the Company will continue on a going concern basis. The Company has incurred losses, historically, and the ability of the Company to continue as a going concern depends upon its ability to develop profitable operations and to continue to raise adequate financing. Management seeks sources of additional financing to provide continuation of the Company’s operations. In order for the Company to meet its liabilities as they come due and to continue its operations, the Company is solely dependent upon its ability to generate such financing.

There can be no assurance that the Company will be able to continue to raise funds, in which case the Company may be unable to meet its obligations. Should the Company be unable to realize its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded in these financial statements. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

#### **4. PROFIT / LOSS PER SHARE**

The Company has not yet adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share

V1.0 Jul 1, 2025

includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive.

## **5. ACCOUNTING PRONOUNCEMENTS**

### **Periodically Issued Accounting Standards**

The Company has not yet adopted all accounting pronouncements issued by the Financial Accounting Standards Board ("FASB") that would apply to SEC reporting issuers, which Health Advance is not. For illustration only, the guidance on how companies account for certain aspects of share-based payments to employees, This pronouncement, for illustration, became effective for fiscal years beginning after December 15, 2016. This guidance called for income tax effects of awards to be recognized in the income statement when the awards vest or are settled and changes the presentation of excess tax benefits on the statement of cash flows. In addition, this pronouncement changes guidance on: (a) accounting for forfeitures of share-based awards and (b) employers' accounting for an employee's use of shares to satisfy the employer's statutory income tax withholding obligation. In the opinion of management adoption of this pronouncement in particular, and similar pronouncements in general, would not have a material impact on Company's financial position and/or results of operations until such time that the scale of the Company's operation expands considerably. The cost and complexity of applying such measures are not feasible, or material, for the Company at the present time. Readers are therefore cautioned that these unaudited internal financial statements may not be suitable for their purposes, notwithstanding the attempt within these statements to present fairly the material conditions of the Company.

## **6. RELATED PARTY TRANSACTIONS AND BALANCES**

The transactions with any related parties are kept within standards that would apply to arm's length transactions unless otherwise specified in the Company's disclosures. Principal amongst non-arm's length transactions are the compensation agreements between the sole director representing shareholders and the president, who are the same person. To mitigate this, compensation is kept within reasonable norms for public company service of this nature, with similar responsibilities and similar risk associated with the exercise of fiduciary responsibilities, including public and regulatory accountability.

## **7. CONTINUITY**

The financial statements of Health Advance were audited up to and including the 2016 fiscal year. Former management undertook to vend in business projects that would have required international auditing that exceeded the company's financial resources relative to the potential value of the vend-in. Former management did not therefore carry on with auditing. The current  
V1.0 Jul 1, 2025

information disclosure filed with OTC Markets under the Alternative Reporting Guidelines resets to the present from the last audited trial balance, rather than from the unaudited EDGAR Q filings, and does not merge largely non-cash subsequent activity in the interests of present clarity and reality. Only known assets are recorded. Liabilities which are statute-barred or forgiven are reflected as recoveries. This serves the cause of accuracy of the current information by avoiding unsubstantiated presumptions, and restoring simple, materially reliable and up-to-date presentation of the present conditions. Management believes that no taxes are payable due to the absence of profit to-date and substantial tax loss carry-forwards. The Company may amend any aspect of the financial statements and other disclosure if new information calls for restatement of any fact.